Results 181 to 190 of about 10,225,052 (294)
Same-sex love and marriage: understanding the Special Marriage Act, 1954. [PDF]
Gomes TC, Kanungo S, Sengupta S.
europepmc +1 more source
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
Dose response of nafamostat mesylate for anticoagulation monitoring in pediatric critical care during continuous venovenous hemodiafiltration. [PDF]
Lee S, Kim J, Lee B.
europepmc +1 more source
Targeting p38α in cancer: challenges, opportunities, and emerging strategies
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley +1 more source
Using administrative data to predict the outcomes of prematurity (EB-POC): a protocol for a linkage study from an Australian Neonatal Network. [PDF]
Abdel-Latif M +3 more
europepmc +1 more source
Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta +10 more
wiley +1 more source
Predictors and clinical outcomes of incomplete hemostasis following transradial coronary intervention: the role of activated clotting time and procedural factors. [PDF]
Shin Y +13 more
europepmc +1 more source

